32 results about "Cell vesicle" patented technology

Systems for positioning and / or analyzing samples such as cells, vesicles, cellular organelles, and fragments, derivatives, and mixtures thereof, for electrical and / or optical analysis, especially relating to the presence and / or activity of ion channels.

The invention provides a tumor vaccine and a preparation method thereof. The tumor vaccine comprises cell vesicles from apoptosis tumor cells and an adjuvant. The invention also provides a preparation method of the tumor vaccine. The method comprises the steps of: irradiating tumor cells by ultraviolet ray to realize tumor cell apoptosis, collecting cell vesicles released by the tumor cells; and mixing the cell vesicles with the adjuvant to form the tumor vaccine. The tumor vaccine provided by the invention comprises wide and comprehensive tumor antigen spectrums, overcomes the defect of incapability to killing wide tumor cells in the prior art, and has good usage security and immunization targeting.

The invention relates to a method for modifying ligands on the surfaces of cell vesicles. The method comprises the following steps of (a) connecting diphenyl cyclooctyne onto the surfaces of the cell vesicles; (b) removing free diphenyl cyclooctyne; (c) connecting azide-modified ligands onto the diphenyl cyclooctyne on the surfaces of the cell vesicles; (d) performing purification on the modified cell vesicles. Compared with the prior art, the method has the advantages that the time is saved; the process is simple and convenient; the reaction efficiency is high; the ligand types are slightly limited; meanwhile, the physiological activity of the cell vesicles can be maintained to the maximum degree. The treatment effect of the cell vesicles can be favorably enhanced.

The invention discloses a macrophage drug-loaded MP (microparticle) preparation and a preparation method thereof. The macrophage drug-loaded MP preparation comprises cell vesicles and drug small molecule effective components wrapped in the cell vesicles, wherein the cell vesicles are released by apoptosis of mannose modified macrophages. The drug-loaded microparticles can be highly enriched in tumor tissue and more easily absorbed by M2 type tumor-related macrophages, the antipolarization effect of small molecule drugs on M2 type tumor-related macrophages is improved, the tumor microenvironment is improved, killing of tumor cells is enhanced, the problems that small molecule drugs cannot be effectively enriched or target and antipolarize M2 type tumor-related macrophages at tumor sites canbe solved, and toxic and side effects of the small molecule drugs on organisms are also reduced.

The invention provides an oncolytic virus preparation and a preparing method thereof. The oncolytic virus preparation comprises cell vesicles coming from apoptotic tumor cells and oncolytic viruses which are wrapped in the cell vesicles and serve as effective constituents. According to the oncolytic virus preparation, as the cell vesicles coming from the cells are used for wrapping the oncolytic viruses, the oncolytic viruses escape from attacks of an organism immune system and can reach the tumor treatment positions in a targeted manner, and the tumor killing effect is improved.

The invention provides a tumor drug-loaded microparticle preparation and a preparation method thereof. The drug-loaded microparticle preparation includes tumor stem cell apoptosis released cell vesicles and a chemotherapeutic drug wrapped in the cell vesicles as an effective component; and is prepared by mixed culture of a three-dimensional soft fibrin glue and tumor cells in a medium. The tumor drug-loaded microparticle provided by the invention is more beneficial to high enrichment in tumor tissue and deep penetration of tumors and can achieve effective uptake by common tumor cells and tumorstem cells more easily, can improve the killing power of the chemotherapeutic drug to common tumor cells and tumor stem cells, can solve the problem that common tumor cell derived drug-loaded microparticles cannot permeate to the depth parts of tumors to kill a lot of tumor stem cells, and at the same time can reduce the toxic and side effect of the chemotherapeutic drug on the body.

Inhibitors of syndapin I binding to dynamin I (DynI) are provided. Examples include mimetics of a region of DynI including the serine residues S774 and S778 or phosphorylatable amino acids in homologous positions. Typically, the mimetics exclude or do not imitate at least one phosphorylation site provided by the serine residues or phosphorylatable amino acids. Peptide fragment inhibitors comprising or consisting of this region of DynI are also described. The inhibitors have application in the prophylaxis or treatment of neurological diseases or conditions. The inhibitors can also be used to inhibit neuronal cell vesicle trafficking and synaptic signal transmission.

The invention provides a tumor vaccine and method for producing the same. The tumor vaccine comprises cell vesicles derived from apoptotic tumor cells and an adjuvant. The invention further provides a preparation method of the tumor vaccine, comprising the steps of using the UV to irradiate the tumor cells to induce apoptosis, and collecting the cell vesicles released from the apoptotic tumor cells and then mixing the cell vesicles with the adjuvant to form the tumor vaccine. The tumor vaccine provided by the invention contains a broad and comprehensive tumor antigen spectrum, the defect that the existing tumor vaccine cannot have the killing capacity against the broad tumor cells can be overcome, and at the same time the tumor vaccine has good use safety and immune targeting property.

The invention provides a method for storing a tumor cell vesicle preparation, belonging to the field of pharmaceutical preparation preservation. The cell vesicle preparation is a cell vesicle derivedfrom an apoptotic tumor cell. As in that prior art, the tumor cell vesicle preparation is refrigerated at 4 DEG C and can only remain stable in function for 48 hours. The method of the invention can freeze the tumor vesicle preparation for a long time at -20 DEG C only by lowering the temperature gradient and keep its biological function. The method solves the problem of storage timeliness of tumor cell vesicle preparation, facilitates mass production and large-scale cryopreservation, thereby greatly reduces production cost and improves production efficiency.

The invention is applicable to the technical field of cells, and provides an apparatus for promoting cells to release vesicles, and a method for promoting the cells to release the vesicles. The apparatus includes: a cell delivery device connected to a device for the cells to release the vesicles and used for delivering cultured concentrated cells to device for the cells to release the vesicles ;and the device for the cells to release the vesicles, including a container and an irradiation lamp, wherein the irradiation lamp is fixed on the container, and the cells are irradiated under preset conditions for a predetermined time to make the cells release the vesicles. The apparatus and the method realize the induction of cell apoptosis in order to make the batch operation for promoting the release of the vesicles by the cells convenient.

The invention belongs to the technical field of biological medicines, and discloses a cell vesicle for expressing a chimeric antigen receptor as well as a preparation method and application of the cell vesicle. The preparation method comprises the following steps: expressing a single-chain variable fragment aiming at the novel coronavirus on a cell membrane, then directly collecting or extruding cell vesicles containing expression chimeric antigen receptors, and finally loading anti-novel coronavirus such as remdesivir and the like on the cell vesicles for treating patients infected by the novel coronavirus. The prepared cell vesicle can specifically neutralize the novel coronavirus and block invasion of the novel coronavirus to cells with high expression of ACE2; meanwhile, anti-novel-coronavirus drugs such as remdesivir and the like can be transported to a novel coronavirus aggregation part in a targeted manner, so that the toxic and side effects of the drugs are reduced. Moreover, the treatment method has universality and can be used as a platform technology to be applied to treatment of other virus infections.

The invention relates to a carboxymethyl chitosan modified drug-carrying vesicle. The drug-carrying vesicle is characterized in that a lipid bilayer membrane of an extracellular vesicle is coated or modified by carboxymethyl chitosan. The molecular weight of the carboxymethyl chitosan is from 165 to 119000, and the deacetylation degree is more than or equal to 50%. The drug-carrying vesicle comprises one or more medicines selected from diclofenac sodium, insulin, paclitaxel, cisplatin, doxorubicin, sipeimine and the like. According to the invention, the carboxymethyl chitosan is connected to the surface of the extracellular vesicle, and modification of the carboxymethyl chitosan changes the surface property of the extracellular vesicle and has profound influence on the drug delivery mechanism of the extracellular vesicle. Compared with a common extracellular vesicle, the drug-carrying vesicle is targeted to tumor cells. A preparation prepared from the carboxymethyl chitosan modified drug-carrying vesicle has more cell vesicles under a condition of ingestion in tumors.

The invention provides an application method of a cell vesicle in the preparation of an oral tumor vaccine. The oral tumor vaccine is a cell vesicle derived from an apoptotic tumor cell, an immunization subject firstly undergoes antacid pretreatment, and then the cell vesicle achieves immunoprophylaxis in an oral perfusion inoculation manner. The oral tumor vaccine can be extremely easily absorbedby the intestinal tract, causes strong immune response, and has a far better use effect than injected tumor vaccines.

The invention relates to a preparation method of a bionic siRNA nano complex with anticancer activity. The preparation method comprises the following steps: (1) preparing a PLGA-PEI polymer by a one-step amidation method; (2) extracting endoplasmic omentum of tumor cells by a calcium chloride precipitation method; (3) preparing PLGA-PEI cation nanoparticles through a film dispersion method and ultrasonic assistance; and (4) loading a siRNA drug, and externally modifying the endoplasmic reticulum membrane to obtain the EPP / siRNA nano complex. According to the invention, the preparation method of the bionic siRNA nano complex with anticancer activity aims to solve the key scientific problems of enhancing the accumulation infiltration capacity of nanoparticles at a tumor site and improving the antitumor curative effect; and by means of active protein for regulating cell vesicle transport in endoplasmic reticulum membrane, the nano complex is endowed with unique transcellular endocytosis capability, the purposes of enhancing accumulation of tumor sites across vascular endothelial cells and enhancing deep penetration of tumor tissues across tumor cells are achieved, and stronger gene silencing and anti-tumor effects are achieved.

The invention relates to a recombinant adenovirus nucleic acid wherein the gene encoding protein V and / or the gene encoding protein VII is placed under control of a heterologous promoter, to a recombinant adenovirus nucleic acid wherein the adenoviral nucleotide sequence is mutated in such a way that it is no longer capable of producing one or more of the coat proteins, to cellular vesicles filled with such adenoviral material, cells provided with such adenoviral material and to methods and use thereof.

A microfluidic control system and method for separating flexible particles such as cell vesicles or biomacromolecules such as exosomes in a sample. The system of the present invention comprises one or more ultrahigh frequency acoustic resonators. The ultrahigh frequency acoustic resonators are capable of generating in a fluid channel an acoustic wave of which the frequency is about 0.5-50 GHz and propagated towards a wall opposite the fluid channel. By adjusting the power of the generated acoustic wave and / or the speed at which a conditioning solution flows through an acoustic wave area, flexible particles in a specified range are pushed to and remain at the top part of the flow channel in the acoustic wave area, while flexible particles outside of the specified range go downstream via the acoustic wave area to be collected, thus capturing or releasing the flexible particles in a solution such as cell vesicles or biomacromolecules, particularly exosomes.

The present invention relates to compositions and methods for displaying proteins and polypeptides on the surface of cells and vesicles. Also disclosed herein are methods and compositions for the delivery of drugs and vaccines utilizing the cell surface display systems of the present invention.

The invention relates to a recombinant adenovirus nucleic acid wherein the gene encoding protein V and / or the gene encoding protein VII is placed under control of a heterologous promoter, to a recombinant adenovirus nucleic acid wherein the adenoviral nucleotide sequence is mutated in such a way that it is no longer capable of producing one or more of the coat proteins, to cellular vesicles filled with such adenoviral material, cells provided with such adenoviral material and to methods and use thereof.

The invention provides a cell apoptosis inducer, a drug-loaded vesicle and application thereof, and belongs to the technical field of biology. The apoptosis inducer comprises an effective amount of yeast mannan and an effective amount of calcium ions. The yeast mannan is used as a calcium ion carrier, the permeability of cell membranes to the calcium ions can be improved, high-concentration free calcium ions can be gathered in cells within a short time, then a cell apoptosis procedure is triggered, cell vesicles are generated, and the obtained cell vesicles are high in yield, good in uniformity and small in average cell vesicle diameter. When the cell vesicle is used for wrapping a drug, the cell vesicle can efficiently pass through the barrier of tumor cells and is endocytosed by the tumor cells, so that the drug delivery efficiency is improved.

The present invention relates to compositions and methods for displaying proteins and polypeptides on the surface of cells and vesicles. Also disclosed herein are methods and compositions for the delivery of drugs and vaccines utilizing the cell surface display systems of the present invention.

The invention discloses a KGM modified lecithin loaded NADH transdermal ethosome, belonging to the technical field of medicinal preparation production. The ethosome is prepared from the following components by weight percent: 1.05-1 percent of NADH, 0.03-10 percent of konjac glucomannan, 1-10 percent of phospholipids, 0.02-1 percent of cholesterol, 0.1-0.5 percent of a stabilizing agent, 0-1 percent of an antioxidant, 5-50 percent of low molecular weight alcohol and the balance of water. The ethosome can be used for solving the problems that NADH is easily enzymolysed, has short biological half-life period and poor stability, has a novel multi-cell vesicle structure having a spherical or spheroidal shape, has more stable thermodynamic property, smaller grain size and higher encapsulation efficiency, has more rapid and stronger transdermal performance and skin tolerance, so that the dosage can be reduced, occurrence of adverse reaction can be reduced, and safety can be improved. The invention further discloses gel containing the ethosome and a preparation process of the ethosome and gel. The gel has fine texture and good human body absorption, and the preparation process is simple,has mild condition, and is suitable for industrial volume production.

Disclosed herein is a biomolecule detection device (1) for analyzing cells, vesicles or cell or vesicle components, comprising an evanescent illuminator having a light coupling unit configured for generating an evanescent field on a first surface of the evanescent illuminator from coherent light (L) having a predetermined wavelength, the first surface of the evanescent illuminator comprises a template nanopattern (5) comprising a coherent arrangement of a plurality of predetermined lines along which membrane recognition elements for transmembrane proteins (81), preferably laterally diffusible transmembrane protein conjugate structures (82), of cells, vesicles or cell or vesicle components (8) are arranged. The membrane recognition element (53) is configured to bind to a conjugate structure (82) of a transmembrane protein (81) to form a transmembrane nanopattern within a cell, vesicle or cell or vesicle component (8) based on a template nanopattern (5) of the evanescent illuminator such that light of the evanescent field is scattered by the cell, vesicle or cell or vesicle component (8) bound to the membrane recognition element (53). The predetermined lines are arranged such that the light scattered by the cells, vesicles or cell or vesicle components (8) bound to the membrane recognition element (53) constructively interferes at a predetermined detection site (7), the difference in optical path length being an integer multiple of the predetermined wavelength of the coherent light (L).